Saturday 17 October 2026
Export RADX’s income statement to Excel — free account
Radiopharm Theranostics Limited - Sponsored ADR
RADX Healthcare Biotechnology
Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
1.03
0.05
−4.63%
Follow RADX
Radiopharm Theranostics Limited - Sponsored ADR (RADX) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DYAI Dyadic International Inc. compare | n/m |
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| ACGN Aceragen, Inc. compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| ATYR aTyr Pharma, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.2× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)